| Original language | English |
|---|---|
| Article number | 22BR14725 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 84 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2023 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Clinical Psychiatry, Vol. 84, No. 5, 22BR14725, 2023.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis
AU - de Leon, Victoria C.
AU - Kumar, Arun
AU - Nagele, Peter
AU - Palanca, Ben J.
AU - Gott, Britt
AU - Janski, Alvin
AU - Zorumski, Charles F.
AU - Conway, Charles R.
N1 - Funding Information: Published Online: August 16, 2023. https://doi. org/10.4088/JCP.22br14725 ©2023 Physicians Postgraduate Press, Inc. J Clin Psychiatry 2023;84(5):22br14725 Submitted: November 10, 2022; accepted April 17, 2023. To Cite: de Leon VC, Kumar A, Nagele P, et al. Nitrous oxide reduced suicidal ideation in treatment-resistant major depression in exploratory analysis. J Clin Psychiatry. 2023;84(5):22br14725. Author Affiliations: Department of Psychiatry, Washington University School of Medicine in St Louis, Missouri (de Leon, Gott, Janski); Bristol Myers Squibb, Lawrenceville, New Jersey (Kumar); Department of Anesthesia and Critical Care, University of Chicago Medical Center, Illinois (Nagele); Department of Anesthesiology and Department of Psychiatry, Washington University School of Medicine in St Louis, Missouri (Palanca); Department of Psychiatry, Washington University School of Medicine in St Louis and Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St Louis, Missouri (Zorumski, Conway). Corresponding Author: Victoria C. de Leon, MD, 660 South Euclid Ave, MSC 8134-0017-04, St Louis, MO 63110 ([email protected]). Relevant Financial Relationships: Drs de Leon, Kumar, and Janski and Ms Gott have no relevant financial relationships. Although Dr Kumar is affiliated with Bristol Myers Squibb; the company is in no way involved with this work, and Dr Kumar contributed to the work in his individual capacity. Dr Nagele has filed for intellectual property regarding nitrous oxide in major depression (“Compositions and methods for treating depressive disorders”; US20170071975A1). Dr Palanca has a patent pending on control of anesthetic state modulation and an agreement with Elemind on the use of non-pharmacologic potentiation of EEG slow waves. Dr Zorumski is on the Scientific Advisory Board of Sage Therapeutics and has equity in the company. Sage Therapeutics was not involved in this work. Dr Conway is on the Sage Therapeutics Advisory Board and has been a consultant for LivaNova, PLC. Funding/Support: This work has no direct funding sources. Data used in this secondary analysis came from trials with the ClinicalTrials.gov identifiers NCT02139540, NCT03283670, and NCT02994433. These trials were supported by the Departments of Anesthesiology and Psychiatry and the Taylor Family Institute for Innovative Psychiatric Research at Washington University School of Medicine, St. Louis, Missouri; NARSAD Independent Investigator Award from the Brain and Behavior Research Foundation; and National Institute of Mental Health (NIMH). Dr de Leon is supported by Washington University Institute of Clinical and Translational Sciences, UL1 TR002345 and sub-award TL1 TR002344. Dr Nagele is receiving funding from NIMH, American Foundation for Suicide Prevention, and Brain and Behavior Research Foundation. Dr Palanca is supported by the Washington University Center for Perioperative Mental Health grant number P50 MH122351 from NIMH and NIMH grant U01MH128483. Dr Zorumski receives support from MH122379 and the Taylor Family Institute for Innovative Psychiatric Research. Dr Conway is supported by the American Foundation for Suicide Prevention, Barnes Hospital Foundation, Taylor Family Institute for Innovative Psychiatric Research, August Busch IV Foundation, and research funding through Washington University from LivaNova, PLC, and is the lead investigator of the RECOVER Trial. Previous Presentations: Presented at Translational Science 2023, Washington, DC, April 18–20, 2023; 2023 SOBP Annual Meeting, San Diego, California, April 27–29, 2023; and 2023 IASR/AFSP International Summit on Suicide Research, Barcelona, Spain, October 15–18, 2023.
PY - 2023
Y1 - 2023
UR - http://www.scopus.com/inward/record.url?scp=85168069033&partnerID=8YFLogxK
U2 - 10.4088/JCP.22BR14725
DO - 10.4088/JCP.22BR14725
M3 - Article
C2 - 37585253
AN - SCOPUS:85168069033
SN - 0160-6689
VL - 84
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 5
M1 - 22BR14725
ER -